about
Neuromyelitis optica pathogenesis and aquaporin 4Molecular pathogenesis of neuromyelitis opticaAquaporin-4 antibodies are not related to HTLV-1 associated myelopathyDevic's neuromyelitis optica: a critical review.Neuromyelitis optica in Brazil: a study on clinical and prognostic factors.Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional studyNMO in pediatric patients: brain involvement and clinical expression.Conventional brain MRI in neuromyelitis optica.New insights into neuromyelitis opticaNeuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience.Brain abnormalities in neuromyelitis optica spectrum disorder.A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran.Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica.Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry.EFNS guidelines on diagnosis and management of neuromyelitis optica.Neuromyelitis Optica-AQP4: an update.Evidence-based review of therapeutic plasma exchange in neurological disorders.Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project.Monitoring neuromyelitis optica activity.Epidemiology of neuromyelitis optica in Latin AmericaPatients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease.Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics.Differences in the progression of primary progressive multiple sclerosis in Brazilians of African descent versus white Brazilian patients.Brain magnetic resonance imaging findings in relapsing neuromyelitis optica.Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients.Neuromyelitis optica: phenotypic characteristics in a Brazilian case series.Recurrent optic neuromyelitis with endocrinopathies: a new syndrome or just a coincidence?Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase.Neuromyelitis opticaEndocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody.HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis
P2860
Q21245240-5416AA40-A60A-4377-A45A-D8B8E3DD116CQ27021535-32822355-C33C-448F-8E30-313519F1E0BCQ28727305-367E5141-8177-4DAA-BEAD-5926AABF6D7AQ31151651-23898E93-B88E-49CC-9990-72BF2B71BC1CQ33419781-B3C45A33-68FF-446A-A785-D7287236DA29Q33568958-68D9DC2E-2B16-49C2-AFF6-FE836D78237EQ33832182-53F76020-DED9-4CC8-96FC-07F4125B2BF6Q34062883-31CC251B-D823-4088-9284-D00F7AD479EDQ35539641-B1C01E95-5C8D-41E0-A536-015E2F18D629Q35785230-DE334C70-2CCA-4B98-A0FF-9D49123DB176Q36457932-274CEFEE-7877-424B-ACB1-63574F2733AAQ36582951-FDEFB6F0-14F4-41EA-8E6D-ED6D1FC81C4EQ36650640-D0C983CD-4F88-4CE0-9D49-120CE0E76874Q37345510-B8AFCA17-026B-4F6C-8972-557AC86846B0Q37763266-0CE0258F-3802-41FD-94C7-D1EB56FBF0AFQ37933091-60809415-EFFC-4051-9D71-7564F7F7D463Q37978670-F7C17721-010D-4923-BA07-3D0939160428Q38009295-0C8010A4-D455-430B-8C2B-0E257F0031DCQ38074625-E95D2E94-3809-4A85-B424-47C4E9794709Q38088747-CD341FAF-53DB-4189-BC46-13A09B026F1BQ38130899-79324B4B-7829-4522-A71D-F3802B73046FQ38140020-CD0E71E0-089D-4CB4-8D14-003A11A9EE9DQ41985689-D9D0328E-5346-4373-88E4-4ECE4BF923BBQ43752309-A607C428-B1F2-4D69-B127-2FC95A85FE0FQ44713880-6838D44B-7D3D-438D-8FC5-4964398855EFQ46319288-E3CD1664-1411-498D-A675-6CBA802F21B2Q48199595-0C9E42AD-89BA-437F-818D-C9804EF9EF78Q48333927-E3BB04BE-E41C-4E4B-8E35-F441B9D57DBEQ51127299-C25C8896-67CD-4751-B18A-67F20DC1C5FBQ51777774-ADF76983-F3C2-4924-B9EF-10B151DF89BEQ53813269-FC0A008E-BB93-41A0-8D51-286D17801853Q54262908-8299D4B0-9FD7-4129-B604-C75234B9545AQ54688254-7CA8CE4F-2523-4AF4-92A3-9DCA4A13766EQ58851197-8BAFD899-9B34-434E-BCED-82CAE2FBB81E
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Optic neuromyelitis syndrome in Brazilian patients
@ast
Optic neuromyelitis syndrome in Brazilian patients
@en
type
label
Optic neuromyelitis syndrome in Brazilian patients
@ast
Optic neuromyelitis syndrome in Brazilian patients
@en
prefLabel
Optic neuromyelitis syndrome in Brazilian patients
@ast
Optic neuromyelitis syndrome in Brazilian patients
@en
P2093
P2860
P356
P1476
Optic neuromyelitis syndrome in Brazilian patients
@en
P2093
Alvarenga H
Basilio De Oliveira CA
Miranda-Santos CM
Oliveira S
Papais-Alvarenga RM
Puccioni-Sohler M
de Almeida AM
P2860
P304
P356
10.1136/JNNP.73.4.429
P407
P577
2002-10-01T00:00:00Z